Brookfield (BN) Q3 FY25 earnings call: guidance and Q&A

Could AI and humanoid partnerships (e.g. Figure) become another leg of the stool, and how do the ~$2.6B of capital-allocation DE components in the 2030 guide unpack?

Goodman split it in two: most capital and focus is on building the backbone AI infrastructure (compute plus the power to supply it), where Brookfield's renewable/nuclear expertise and forthcoming data-center/AI fund position it well. The Figure/humanoid investment is more defensive/strategic — deployed selectively for the benefit of the broader organization rather than as a standalone next leg.

“I don't think of this as necessarily the next leg. I think it's a force and a trend that's driving broad growth across the organization, and we're well positioned to participate in it.”

asked by Michael Cyprys · answered by Nicholas Goodman

How long to reach the ~200 bps net investment yield spread, and how will gross vs net insurance flows evolve (net was ~40% of gross this quarter)?

The 200 bps is a medium-to-long-term target requiring patient, barbell deployment (short-term liquidity balanced with real-asset/credit/equity investment), so it will take time; management emphasizes ROE (compounding 15%+) over spread. Gross-to-net flows should stabilize to roughly one-third outflows versus inflows per quarter.

“On the gross to net flows, it should stabilize out to about 1/3 outflows versus inflows in a quarter as we move forward.”

asked by Mario Saric · answered by Nicholas Goodman

Has the ~$3B Oaktree purchase-price split between BAM/BN shares and cash been settled, and will it slow BN buybacks?

Elections are finalized: roughly $250M of BN shares elected, the balance in cash, and almost 100% of the BAM consideration in cash. It will have zero impact on the broader buyback strategy — Brookfield will repurchase the $250M of shares it issues but continue its normal buyback pace.

“it will have zero impact on our buyback. We will buy back the 250 million of shares that we issue, but it won't have impact on our broader buyback strategy.”

asked by Mario Saric · answered by Nicholas Goodman

Annuity spread was ~165 bps this quarter — what are the near-term dynamics as you earn back toward targets?

The 165 bps reflects deliberate discipline and patient deployment; Brookfield is sourcing attractive real-asset credit and equity opportunities and runs the business for the long term, not quarter to quarter. As capital is put to work the spread should widen back toward long-term targets, but ROE remains the key governing metric.

“as they come in, you'll start to see that spread widen out. But again, what it all comes back to is the ROE.”

asked by Alexander Blostein · answered by Nicholas Goodman

How is the Just acquisition progressing and what could it mean financially/strategically for UK and European growth?

Management is limited in what it can disclose and hasn't shared pro-forma figures while working through regulatory approvals; shareholder vote is done and it is engaging the regulator (prior UK licensing gives a relationship with the PRA). Just has a strong PRT track record (~£5B origination the year before acquisition), which Brookfield expects to continue and scale with its capital.

“Just has got a good track record of issuing PRT on a consistent basis in the U.K., I think in the year before we acquired them about GBP 5 billion of origination.”

asked by Alexander Blostein · answered by Nicholas Goodman

What downside protection would Brookfield/LPs seek in nuclear development, and would it sit in a discrete nuclear strategy or DGTF?

The $80B is bought by the US government as equity investor via Westinghouse; Brookfield's role is to deliver facilities and provide fuel/servicing, effectively scaling the existing Westinghouse services model (held within BGTF), not taking direct development risk. For future plans (e.g. South Carolina), any involvement would be structured for strong downside protection, though it is early days.

“anything that we would do in the space where we're looking to get involved... would be structured in a way to provide strong downside protection.”

asked by Cherilyn Radbourne · answered by Nicholas Goodman

How is carry shaping up for 2026 given a better M&A/realization environment, and how does the realization outlook split between balance sheet and Brookfield funds?

The carry outlook is unchanged — 2025 a bridge year consistent with 2024, with a step-up in 2026, again into 2027, and a strong 2028. Fund monetizations proceed independently across a globally diversified portfolio; on the balance sheet (US office/retail), capital markets are even stronger than last quarter, with financings at rates unachievable a month earlier and returning acquisition appetite pointing to more activity into next year.

“We had very successful financings in the quarter at spreads and all-in rates we couldn't have achieved even a month ago, and that all lends itself very favorably towards increasing transaction activity.”

asked by Kenneth Worthington · answered by Nicholas Goodman

What drove the LP real estate NOI step-up to ~$465M, and will target carry rise once the Oaktree deal closes?

The LP portfolio's step-up in FFO was driven by disposition gains from monetizations on top of running returns. On target carry, owning more of Oaktree adds carry-eligible capital so target carry will pick up, but not materially.

“during the quarter, we benefited from disposition gains from monetization and that's what's driving the increase... in the FFO during the quarter.”

asked by Bart Dziarski · answered by Nicholas Goodman